Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Stem Cell Transplantation in Children with Infantile Osteopetrosis Is Associated with a High Incidence of VOD, Which Could Be Prevented with Defibrotide.

View through CrossRef
Abstract Background: Malignant infantile osteopetrosis (MIOP) is a rare hereditary disorder of osteoclast function, which can be reversed by hematopoietic stem cell transplantation (SCT). In recent studies defibrotide (DF) demonstrated superior efficacy in the treatment of hepatic veno-occlusive disease (VOD). Methods: Twenty children with MIOP were consecutively transplanted in our centre between 1996 and 2005. Eleven of these patients were transplanted between 1996 and 2001 without any VOD prophylaxis. Thereafter nine patients were transplanted between 2001 and 2005 with prophylactic DF from the first day of conditioning until 30 days after SCT because we observed a high incidence of VOD in transplanted patients and explored the prevention of this complication by using DF as a prophylaxis. Results: Patients without DF experienced an overall incidence of VOD of 63.6% (7/11). VOD was severe in three patients and one patient succumbed to VOD related multiorgan failure (MOF). In nine patients consecutively transplanted between 2001 and 2005 only one patient (11.1%) was diagnosed with moderate VOD. Conclusion: SCT in patients with MIOP is associated with a very high risk to develop VOD. Prophylactic DF was implemented in our current transplant protocol and reduced the VOD rate dramatically in this high risk population.
Title: Stem Cell Transplantation in Children with Infantile Osteopetrosis Is Associated with a High Incidence of VOD, Which Could Be Prevented with Defibrotide.
Description:
Abstract Background: Malignant infantile osteopetrosis (MIOP) is a rare hereditary disorder of osteoclast function, which can be reversed by hematopoietic stem cell transplantation (SCT).
In recent studies defibrotide (DF) demonstrated superior efficacy in the treatment of hepatic veno-occlusive disease (VOD).
Methods: Twenty children with MIOP were consecutively transplanted in our centre between 1996 and 2005.
Eleven of these patients were transplanted between 1996 and 2001 without any VOD prophylaxis.
Thereafter nine patients were transplanted between 2001 and 2005 with prophylactic DF from the first day of conditioning until 30 days after SCT because we observed a high incidence of VOD in transplanted patients and explored the prevention of this complication by using DF as a prophylaxis.
Results: Patients without DF experienced an overall incidence of VOD of 63.
6% (7/11).
VOD was severe in three patients and one patient succumbed to VOD related multiorgan failure (MOF).
In nine patients consecutively transplanted between 2001 and 2005 only one patient (11.
1%) was diagnosed with moderate VOD.
Conclusion: SCT in patients with MIOP is associated with a very high risk to develop VOD.
Prophylactic DF was implemented in our current transplant protocol and reduced the VOD rate dramatically in this high risk population.

Related Results

Defibrotide in Prevention of Liver Toxicity in Patients at High Risk of VOD after HSC Transplantation.
Defibrotide in Prevention of Liver Toxicity in Patients at High Risk of VOD after HSC Transplantation.
Abstract Defibrotide has been proposed as preventive treatment of Veno Occlusive Disease (VOD), data on its use are, however, limited and its effectiveness not yet d...
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
PROFIBRINOLYTIC ACTIVITY OF DEFIBROTIDE IS PTOSTACYCLIN-INDEFENDEMT
PROFIBRINOLYTIC ACTIVITY OF DEFIBROTIDE IS PTOSTACYCLIN-INDEFENDEMT
The profibrinolytic, antithrombotic and thrombolytic activities of Defibrotide, a polydeoxyribonucleotide obtained from mammalian lungs, have been previously described. Defibrotide...
DEFIBROTIDE IN EXPERIMENTAL MYOCARDIAL ISCHEMIA IN THE CAT: EFFECTS ON HEMODYNAMICS, ENERGY METABOLISM AND INFARCT SIZE
DEFIBROTIDE IN EXPERIMENTAL MYOCARDIAL ISCHEMIA IN THE CAT: EFFECTS ON HEMODYNAMICS, ENERGY METABOLISM AND INFARCT SIZE
Defibrotide was able to prevent the hemodynamic and biochemical alterations caused by acute myocardial ischemia (AMI) induced by coronary occlusion in the cat when infused 3.5 h be...
Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel
Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel
No biomarker panel is established for prediction of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), a major complication of allogeneic stem cell transplantation (...
Osteopetrozis
Osteopetrozis
Osteopetrosis is a descriptive term that refers to a group of rare, inherited bone disorders first described in 1904 by Albers Schönberg.[] Three forms of this disease have been de...
Beneficial Effects of Defibrotide against Myocardial Ischemia and Decline of β-Adrenoceptor Function in the Rabbit
Beneficial Effects of Defibrotide against Myocardial Ischemia and Decline of β-Adrenoceptor Function in the Rabbit
Defibrotide is a polydeoxyribonucleotide of mammalian origin which possesses profibrinolytic effect and PGI<sub>2</sub>-releasing capacity. Because of these properties,...

Back to Top